AbCellera Biologics reported $56.0M of remaining performance obligations at 30 Jun 2026.
30% of the backlog is due within the next twelve months.
Customer prepayments (contract liabilities) cover 109.3% of the backlog.
By backlog size it ranks 459th among US filers the cockpit tracks.
AbCellera Biologics backlog history
Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).
Amounts in USD. Source: SEC XBRL filings.
Quarter end
Backlog (RPO)
TTM revenue
Coverage
Customer prepayments
30 Jun 2026
$56.0M
n/a
n/a
$61.2M
Questions
What is AbCellera Biologics's backlog?
AbCellera Biologics reported $56.0M of remaining performance obligations at 30 Jun 2026.
About these numbers
Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.